Grant: Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
University of Toronto
$120,000.00
Computationally Engineered Mucosal circRNA Vaccine with ATRA Adjuvant for Broad HIV-1 Protection.
EF 2024-25
Résumé
HIV-1 is a major global health issue affecting 36.1-44.6 million people worldwide according to the World Health Organization (WHO). Unfortunately, HIV-1 disproportionately impacts the LGBTQ community, Indigenous Canadians, women, and sex workers. The COVID-19 pandemic strained our healthcare system, leading to a rise in new HIV-1 cases, creating a "silent pandemic." Developing an HIV-1 vaccine is challenging due to the virus's high mutation rate, rapid replication at mucosal sites, and unclear vaccine protection markers, highlighting the urgent need for a solution.
Unlike linear mRNA vaccines, circular RNA (circRNA) is more stable and unlikely to trigger unwanted immune responses. We aim to build on the success of mRNA vaccines by developing a mucosal circRNA vaccine specifically for HIV-1. To enhance the effectiveness of our circRNA vaccine, we propose combining it with all-trans retinoic acid (ATRA). Research showed that ATRA-treated mice increased CCR9 and CD103 expression on effector T-cells, helping them persist in mucosal sites, which is crucial for preventing viral spread.
Our hypothesis is that combining circRNA vaccines with ATRA will boost mucosal immune responses, reducing the spread of HIV-1 and its impact.
Our goal is to engineer a vaccine that activates both arms of adaptive immunity and directs immune cells to mucosal sites for effective viral defence. To achieve this, we will design a circRNA vaccine using immunoinformatics to specifically target the HIV-1 virus. Leveraging our expertise in circRNA synthesis and an extensive LNP library, we are well-equipped to develop this vaccine. We will test it in a humanized mouse model (hu-HSC) focusing on antibody production, T-cell activation, and viral neutralization.
This innovative approach combines a circRNA vaccine with ATRA to reduce HIV-1 transmission and disease, particularly in high-risk communities. It also provides a foundation for creating vaccines against other complex viruses.
Programme
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
519414
Name
Selim Alaa S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Computationally Engineered Mucosal circRNA Vaccine with ATRA Adjuvant for Broad HIV-1 Protection.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Keyworddelim
Atra-Adjuvant; Broadly Neutralizing Antibodies (Bnabs); Cd8+ And Cd4+ T-Cell Activation; Circular Rnas (Circrna) Vaccines; Humanized Mice (Hu-Hsc); Immunoinformatic Analysis; Infectious Diseases (Hiv-1); Lipid Nanoparticle (Lnp); Mucosal Barriers; Women And Lgbtq+ Community
Abstract
HIV-1 is a major global health issue affecting 36.1-44.6 million people worldwide according to the World Health Organization (WHO). Unfortunately, HIV-1 disproportionately impacts the LGBTQ community, Indigenous Canadians, women, and sex workers. The COVID-19 pandemic strained our healthcare system, leading to a rise in new HIV-1 cases, creating a "silent pandemic." Developing an HIV-1 vaccine is challenging due to the virus's high mutation rate, rapid replication at mucosal sites, and unclear vaccine protection markers, highlighting the urgent need for a solution.
Unlike linear mRNA vaccines, circular RNA (circRNA) is more stable and unlikely to trigger unwanted immune responses. We aim to build on the success of mRNA vaccines by developing a mucosal circRNA vaccine specifically for HIV-1. To enhance the effectiveness of our circRNA vaccine, we propose combining it with all-trans retinoic acid (ATRA). Research showed that ATRA-treated mice increased CCR9 and CD103 expression on effector T-cells, helping them persist in mucosal sites, which is crucial for preventing viral spread.
Our hypothesis is that combining circRNA vaccines with ATRA will boost mucosal immune responses, reducing the spread of HIV-1 and its impact.
Our goal is to engineer a vaccine that activates both arms of adaptive immunity and directs immune cells to mucosal sites for effective viral defence. To achieve this, we will design a circRNA vaccine using immunoinformatics to specifically target the HIV-1 virus. Leveraging our expertise in circRNA synthesis and an extensive LNP library, we are well-equipped to develop this vaccine. We will test it in a humanized mouse model (hu-HSC) focusing on antibody production, T-cell activation, and viral neutralization.
This innovative approach combines a circRNA vaccine with ATRA to reduce HIV-1 transmission and disease, particularly in high-risk communities. It also provides a foundation for creating vaccines against other complex viruses.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Selim, Alaa S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~